Stock info Novartis | Filter  Basic-Info

Novartis

The past year was a good year for Novartis investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Novartis, the stock lost around 13 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 52 percent. Novartis's revenues between 2011 and 2015 were relatively steady and moved between 52,7 billion CHFF and 50,45 billion CHFF. Novartis's net results between 2011 and 2015 were relatively steady and moved between 10,06 billion CHFF and 8,61 billion CHFF.

Novartis's head office is located in Basel. Novartis is mostly active in the pharmaceutical sector. Novartis is being led by CEO Joseph Jimenez. The past 10 years the (international) industry gained at around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Swiss company paid out dividends in the past 5 years. Over the past 5 years Novartis's dividend yield was at around 12,32 percent per year.

Novartis had about 133,41 thousand employees at the end of 2015.

Novartis' balance mostly consists of equity

At the end of 2015 the Swiss company had a balance sheet of 131,79 billion CHFF. The total debt of the pharmaceutical company was at the end of 2015 54,61 billion CHFF, which equals around 41,43 percent of the total balance sheet. The Swiss company's price/earnings-ratio was 26. So the market valued the stock at 26 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the Swiss company's market capitalization equaled around 205,94 billion CHFF. At the end of 2015 around 2,4 billion stocks were listed.

All of Novartis's annual reports are stored here. More information about Novartis can be found it's website. .